昊海生科(688366) - 昊海生科2024年8月21日投资者关系活动记录表

Group 1: Hyaluronic Acid Product Performance - The company's hyaluronic acid products maintained good growth despite a challenging market, with "Hai Mei" leading in market share and high-value product positioning [2] - The new product "Hai Mei Yue Bai" is expected to differentiate itself in the market and is currently completing production licensing [2] - The global hyaluronic acid market shows significant potential, with injection products holding an 80% market share, indicating strong safety and efficacy recognition [2] Group 2: Customization and Sales Strategy - The company aims to balance self-branded products with customized offerings to meet the diverse needs of medical beauty institutions [2] - The current marketing team for medical beauty products consists of approximately 150 to 200 people, with plans to expand to 200 to 250 to match sales growth [2] Group 3: Research and Development Focus - R&D expenses for the first half of 2024 reached 125 million CNY, a 24% increase year-on-year, accounting for 8.93% of revenue [2] - The company is focusing on a full product line and industry chain participation, including products like botulinum toxin and hydroxyapatite [3] Group 4: Market Dynamics and Pricing Strategy - The gross margin for hyaluronic acid products remains around 70%, with a slight decline compared to the previous year due to balancing high and low-margin products [3] - The company is adopting strategies for overseas expansion through acquisitions and brand development, particularly in the medical aesthetics sector [3] Group 5: Crystal Product Sales and Market Trends - Crystal product revenue declined by 10% in the first half of the year, influenced by pricing adjustments from national procurement [4] - The company anticipates an increase in mid-to-high-end product usage as national procurement progresses, which will positively impact overall revenue and profit margins [4] Group 6: Sales and Marketing Efficiency - The sales expense ratio has decreased, primarily due to reduced promotional costs in ophthalmology, orthopedics, and surgery [4] - The company plans to leverage new product launches to drive market promotion without significantly increasing the overall marketing budget [4]